Half-life
Very short; minutes to hours
Evidence Level
Preliminary
Mechanism of Action
Exerts anti-inflammatory effects by inhibiting NF-κB activation and proinflammatory cytokine production (TNF-α, IL-6, IL-8). Enters cells directly without receptor mediation.
Published Research Ranges & Study Context
Studies have administered: 0.02–2mg/kg in animal studies; oral formulations studied for gut applications
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Animal IBD models show significant mucosal inflammation reduction. Wound healing studies demonstrate accelerated closure and reduced inflammatory markers.
Preliminary
Primarily preclinical + case reports
Side Effects Observed in Research
Excellent safety profile in research; minimal adverse effects documented
Available Configurations (SKU Reference)
KPV5
KPV10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on KPV — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.